Rein Therapeutics (RNTX) Preferred Stock Liabilities (2023 - 2026)
Rein Therapeutics (RNTX) posted quarterly Preferred Stock Liabilities of $45.0 million for Q1 2026, little changed year-over-year from $45.0 million in Q1 2025, and little changed quarter-over-quarter from $45.0 million in Q4 2025.
Rein Therapeutics (RNTX) Preferred Stock Liabilities (2023 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Preferred Stock Liabilities for 4 consecutive years, with $45.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (changed 0.0% YoY), while the FY2025 annual figure was $45.0 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities steadied at $45.0 million in Q1 2026 per RNTX's latest filing, from $45.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $91.4 million in Q4 2023 and bottomed at $45.0 million in Q2 2024.
- Historically, Preferred Stock Liabilities has averaged $49.8 million across 4 years, with a median of $45.0 million in 2024.
- Annual changes were most pronounced in 2024 — Preferred Stock Liabilities plunged 50.77% — and 2025, when it changed 0.0%.
- Rein Therapeutics' Preferred Stock Liabilities stood at $91.4 million in 2023, then slumped by 50.77% to $45.0 million in 2024, then changed by 0.0% to $45.0 million in 2025, then changed by 0.0% to $45.0 million in 2026.
- Business Quant data shows RNTX's Preferred Stock Liabilities at $45.0 million in Q1 2026, $45.0 million in Q4 2025, and $45.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 45.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.01 Mn |
| Mar 31, 2026 | 45.01 Mn |
| Dec 31, 2025 | 45.01 Mn |
| Sep 30, 2025 | 45.01 Mn |
| Jun 30, 2025 | 45.01 Mn |
| Mar 31, 2025 | 45.01 Mn |
| Dec 31, 2024 | 45.01 Mn |
| Sep 30, 2024 | 45.01 Mn |
| Jun 30, 2024 | 45.01 Mn |
| Mar 31, 2024 | 46.58 Mn |
| Dec 31, 2023 | 91.41 Mn |